Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 23 October 1998:
Vol. 282. no. 5389, p. 589
DOI: 10.1126/science.282.5389.589j
Prev | Table of Contents | Next

This Week in Science

Individuals with abetalipoproteinemia have extremely low levels of plasma lipoproteins. This disorder is caused by an inherited deficiency in microsomal triglyceride transfer protein (MTP), a molecule required for assembly and secretion of lipoprotein particles. Wetterau et al. (p. 751) postulated that inhibitors of MTP might have therapeutic potential as cholesterol-lowering drugs. In a high-throughput screen of chemical compounds, they isolated an orally active MTP inhibitor that lowered plasma lipoprotein levels in several animal models, including a rabbit model of hyperlipidemia that is resistant to existing drugs. MTP inhibitors may open up a new avenue for treatment of humans who are at risk for atherosclerosis because of high cholesterol levels.




ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)